K reports of America’s largest pharmaceutical companies show that they continue to avoid paying much, if any, U.S. corporate income tax.
The EC approved the CAR T-cell therapy based on data from a Phase II study showing a 94 percent complete response rate.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback